Gene Expression Profiling for Multiple Myeloma Subgroup Classification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for identifying genes associated with poor prognosis in patients with multiple myeloma, complicating diagnosis and treatment, as they fail to effectively differentiate between normal and malignant plasma cells and various subgroups of multiple myeloma.
Innovation Solution
Gene expression profiling using high-density oligonucleotide microarrays to identify distinct subgroups of multiple myeloma, such as MM1, MM2, MM3, and MM4, and pinpointing genes like FGFR3 and CCND1 involved in DNA metabolism and cell cycle control, which are overexpressed in high-risk cases, enabling accurate diagnosis and potential therapeutic targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic methods (clinical criteria, bone marrow plasmocytosis, monoclonal immunoglobulin concentration) are used to diagnose multiple myeloma, then diagnosis can be established in most cases, but the ability to differentiate between normal and malignant plasma cells and identify distinct subgroups is insufficient
Solution Approach 1:
The patent replaces conventional mechanical/cytological diagnostic methods (examining plasma cell morphology, counting plasmocytosis, measuring immunoglobulin concentrations) with molecular genetic analysis using gene expression profiling. This substitution enables the identification of malignant plasma cells and differentiation of subgroups based on their transcriptional signatures rather than solely on cellular morphology and quantity, thereby resolving the contradiction between establishing diagnosis and capturing comprehensive disease information.
Solution Approach 2:
The patent shifts the diagnostic parameters from traditional clinical and cytological measures (bone marrow cell counts, immunoglobulin levels) to molecular parameters (gene expression profiles). By measuring the expression levels of specific genes (such as those involved in DNA metabolism and cell cycle control), the system achieves more precise differentiation between normal and malignant plasma cells and identification of distinct myeloma subgroups, directly addressing the limitation of conventional methods.
2Quantity of substance
If comprehensive analysis of laboratory parameters (β2-microglobulin, C-reactive protein, plasma cell labeling index, metaphase karyotyping, FISH) is performed, then more clinical information is obtained, but still only about 20% of clinical heterogeneity can be accounted for
Solution Approach 1:
The patent segments the heterogeneous population of multiple myeloma patients into distinct molecular subgroups based on their gene expression profiles. By clustering patients according to the expression patterns of specific genes (particularly those involved in DNA metabolism and cell cycle control), the system identifies reproducible molecular subtypes that better explain clinical heterogeneity than conventional laboratory parameters alone, thereby improving the reliability of predicting patient outcomes and guiding treatment decisions.
Solution Approach 2:
The patent introduces gene expression profiling as an intermediary layer between conventional laboratory parameters and clinical outcomes. Rather than directly correlating laboratory values (β2-microglobulin, CRP, karyotype) with patient prognosis, the system uses gene expression data as a mediator that captures the biological mechanisms underlying these parameters, providing a more comprehensive and reliable explanation for clinical heterogeneity and enabling more accurate prediction of disease course and treatment response.
3Measurement precision
If gene expression profiling using high-density oligonucleotide microarrays is performed, then distinct subgroups of multiple myeloma can be identified and genes associated with poor prognosis can be pinpointed, but the complexity of the analysis and potential false positives increases
Solution Approach 1:
The patent extracts and focuses analysis on a specific subset of genes known to be involved in DNA metabolism and cell cycle control, rather than attempting to analyze all genes simultaneously. By concentrating on these functionally relevant gene families, the system maintains high measurement precision for identifying subgroups and prognostic genes while reducing the complexity of data analysis and minimizing false positives that would arise from examining the entire genome without functional guidance.
Data Source
AI summary
Gene expression profiling is a powerful tool that has varied utility. It enables classification of multiple myeloma into subtypes and identifying genes directly involved in disease pathogensis and clinical manifestation. The present invention used gene expression profiling in large uniformly treated population of patients with myeloma to identify genes associated with poor prognosis. It also demonstrated that over-expression of CKS1B gene, mainly due to gene amplification that was determined by Fluorescent in-situ hybridization to impart a poor prognosis in multiple myleoma. It is further contemplated that therapeutic strategies that directly target CKS1B or related pathways may represent novel, and more specific means of treating high risk myeloma and may prevent its secondary evolution.